d-2570
Small moleculeexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Feb 4, 2024 (NCT06278350)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase TYK2INHIBITOR
TYK2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07311200 | Phase 2 | Jan 15, 2026 | InventisBio Inc. |
| NCT07270783 | Phase 1 | Dec 31, 2025 | InventisBio Inc. |
| NCT07130604 | Phase 3 | Sep 26, 2025 | InventisBio Inc. |
| NCT07035041 | Phase 2 | May 22, 2025 | InventisBio Inc. |
| NCT07275775 | Phase 1 | Aug 13, 2024 | InventisBio Inc. |
| NCT06278350 | Phase 2 | Feb 4, 2024 | InventisBio Inc., Peking University |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| InventisBio Inc. | For profit | 6 | 6 | 3 | 2024 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1